Doheny Eye Institute

01/29/2026

In recognition of Glaucoma Awareness Month, Doheny-UCLA glaucoma specialist Brian A. Francis, MD, MS, shares insights on what’s next in glaucoma care in a recent interview with Glaucoma Physician.

From advances in imaging and genetics to emerging approaches in neuroprotection and patient-centered care, Dr. Francis looks ahead at how glaucoma management continues to evolve.

To read or see the full interview: https://www.glaucomaphysician.net/issues/2026/january/looking-ahead-during-glaucoma-awareness-month/

Brian A. Francis, MD, discusses emerging diagnostics, neuroprotection, and patient-centered advances shaping the future of glaucoma management.

01/28/2026

Happening today at UCLA Ophthalmology Grand Rounds 👁️✨

We’re excited to spotlight Daniel Rootman, MD, Doheny-affiliated oculoplastics expert and Clinical Professor of Ophthalmology at UCLA, moderating an outstanding program focused on complex orbital and ophthalmic plastic surgery cases.

From corneal neurotization to diagnostic challenges beyond Graves’ disease, today’s case presentations and specialty service program reflect the depth, nuance, and innovation shaping oculoplastics care.

📍 RPB Auditorium, UCLA Stein Eye Institute
🕟 Wednesday, January 28 | 4:30 PM

Can’t join in person? Attend virtually via Zoom:
🔗 https://uclahs.zoom.us/j/94319971957

Meeting ID: 943 1997 1957 | Passcode: 008840

This is a must-attend afternoon of learning and discussion!

01/17/2026

Advancing care for patients with retinal vein occlusion.

Join this Grand Rounds–style CME activity, Transforming Care Through Next-Generation Therapies in Retinal Diseases, an expansion of the Vision RELIEF: No Eyes Left Behind initiative. Chaired by Dr. Srinivas Sadda, this program explores how next-generation anti-VEGF therapies may help reduce treatment burden while improving outcomes in RVO.

Through evidence review and case-based discussion, participants will examine efficacy, safety, dosing strategies, and patient selection to better optimize real-world care.

✔️ 1.0 AMA PRA Category 1 Credit™
✔️ 1.0 ANCC contact hour
✔️ No fee to participate

Details and access here:

This Grand Round series will overview current barriers in the treatment of RVO, focusing on the role that next-generation anti-VEGF agents have in addressing these barriers and improving outcomes. The rationale, efficacy, and safety of next-generation anti-VEGF agents will be covered, and case-based...

01/16/2026

January is Glaucoma Awareness Month. Glaucoma can develop without symptoms, making routine eye exams essential. Early diagnosis and personalized care play a critical role in protecting vision. We’re proud to highlight our Doheny glaucoma specialists who are advancing glaucoma care every day.

Protecting vision starts with awareness and expert care.

01/13/2026

Today’s Work-in-Progress meeting featured Peng Shang, PhD, who shared new insights on how the Complement Factor H (Y402H) polymorphism linked to age-related macular degeneration may alter retinal fatty acid metabolism. These sessions spark thoughtful, collegial dialogue and highlight the innovative research happening every day at Doheny Eye Institute as we work to advance vision science.

01/09/2026

Today’s Doheny Distinguished Lecture Series featured an outstanding presentation by Connie Cepko, PhD, Bullard Professor of Genetics and Neuroscience at Harvard Medical School and Investigator at the Howard Hughes Medical Institute.

Dr. Cepko’s talk, “Gene-Agnostic Gene Therapy to Preserve Vision,” offered a compelling look at emerging strategies to protect retinal cells and advance treatments for inherited retinal disease. We’re grateful to everyone who joined us in person and on Zoom for a thoughtful and inspiring discussion.

01/08/2026

A tiny enzyme may play an unexpected role in how diabetic eye disease begins.

Doheny researchers Mahesh Agarwal, Sathishkumar Chandrakumar, Irene Santiago Tierno, Emma Lessieur, and Kaustabh Ghosh recently published new findings in Diabetes that help explain how diabetic eye disease may start long before symptoms appear.

Their research reveals how excess lysyl oxidase (LOX), a naturally occurring enzyme, can stiffen retinal blood vessels and overactivate immune cells, setting off early damage that leads to diabetic retinopathy. By uncovering this chain reaction, the team is opening the door to earlier detection and future therapies aimed at protecting vision before it’s lost.

🔬 Discoveries like this bring us closer to preventing vision loss, not just treating it. Read more at doheny.org.

01/07/2026

Today marks one year since the fires that deeply affected our region.

We pause to remember those who lost homes, businesses, and a sense of normalcy, and to thank the first responders and neighbors who showed extraordinary courage and care. We recognize that recovery takes time, and we continue to hold our community close.

One year later, we remember. We stand with all who lost so much and with those still rebuilding.

01/06/2026

Today we celebrated 40 incredible years of service as Carmen Sanchez officially retired from Doheny Eye Institute.

Throughout the luncheon, one message came through loud and clear: Carmen will be deeply missed. For four decades, she took such genuine care of our faculty and staff, always making sure everyone felt supported, welcomed, and looked after.

Thank you, Carmen, for your dedication, kindness, and the lasting impact you’ve made on the Doheny community. Wishing you a joyful and well-earned retirement. You’ll always be part of the Doheny family 💜

12/24/2025

This season of reflection is a reminder of what we can accomplish together. Thanks to your support, Doheny Eye Institute continues to push the boundaries of vision research—advancing imaging, AI, and discoveries that improve lives around the world. We are deeply grateful for your partnership and belief in our mission.

Sending our warmest wishes to you and your loved ones as the year comes to a close.

12/20/2025

This holiday season, give a gift that truly changes a life.

Your support helps protect sight, restore vision, and fuel breakthroughs that impact generations to come.

Make your year-end gift today and honor someone you love in a meaningful way.

Donate now at Doheny.org/donate

12/17/2025

Happening TODAY at UCLA Stein Eye Institute! 👁️

Join UCLA Stein Eye Institute Grand Rounds this afternoon, Wednesday, December 17 at 4:30 PM, featuring clinical case presentations and a Cornea–External Ocular Disease Specialty Service lecture moderated by Benjamin Bert, MD, FACS.

🩺 Clinical Case Presentations (4:30–5:15 PM)
• Through the Haze: Post-PRK Corneal Haze
John Cheng, MD & Benjamin Bert, MD, FACS
• The Cornea Keeps Receipts
Sydney Wendt, MD & Benjamin Bert, MD, FACS
• Case presentation
Emile Vieta, MD & Benjamin Bert, MD, FACS

👁️ Specialty Service Program (5:15–5:45 PM)
Blepharitis in 2025
Benjamin Bert, MD, FACS
Health Sciences Associate Professor
UCLA Department of Ophthalmology
David Geffen School of Medicine
(and Doheny CME Medical Director)

📍 In person: RPB Auditorium, UCLA Stein Eye Institute
💻 Virtual option available via Zoom
🔗 https://uclahs.zoom.us/j/98999940670

Meeting ID: 989 9994 0670 | Passcode: 111225

Physicians may earn up to 1.5 AMA PRA Category 1 Credits™ through the David Geffen School of Medicine at UCLA
(Please log in using your full name to ensure CME/CE credit.)